{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:48:22Z","timestamp":1791204502357,"version":"4.2.0"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10787-026-02193-7","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:53:54Z","timestamp":1774421634000},"page":"2193-2218","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Drug repurposing against viral infections (2020\u20132025): clinical trials, computational strategies, and therapeutic interventions"],"prefix":"10.1007","volume":"34","author":[{"given":"Sumel","family":"Ashique","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utpal","family":"Bhui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahreen","family":"Taj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Yousuf","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti Maithani","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Sadique","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"2193_CR1","doi-asserted-by":"publisher","first-page":"902123","DOI":"10.3389\/fpubh.2022.902123","volume":"10","author":"F Ahmed","year":"2022","unstructured":"Ahmed F, Lee JW, Samantasinghar A, Kim YS, Kim KH, Kang IS, Memon FH, Lim JH, Choi KH (2022) SperoPredictor: an integrated machine learning and molecular docking-based drug repurposing framework with use case of COVID-19. Front public health 10:902123","journal-title":"Front public health"},{"issue":"2","key":"2193_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11042-023-15805-z","volume":"83","author":"SA Ajagbe","year":"2024","unstructured":"Ajagbe SA, Adigun MO (2024) Deep learning techniques for detection and prediction of pandemic diseases: a systematic literature review. Multimedia Tools Appl 83(2):1\u201335","journal-title":"Multimedia Tools Appl"},{"key":"2193_CR3","doi-asserted-by":"publisher","first-page":"12019","DOI":"10.2147\/DDDT.S576701","volume":"19","author":"AH Al Khzem","year":"2025","unstructured":"Al Khzem AH, Wali SM (2025) Drug repurposing as an effective drug discovery strategy: a critical review. Drug design. Dev therapy 19:12019\u201312034","journal-title":"Dev therapy"},{"key":"2193_CR4","doi-asserted-by":"publisher","first-page":"5682","DOI":"10.1038\/s41598-024-55950-5","volume":"14","author":"RA Ali","year":"2024","unstructured":"Ali RA, Awadalla EA, Amin YA, Fouad SS, Ahmed MAB, Hassan MH, Abdel-Kahaar E, Abdel-Aziz RH (2024) The deleterious effects of sofosbuvir and ribavirin (antiviral drugs against hepatitis C virus) on different body systems in male albino rats regarding reproductive, hematological, biochemical, hepatic, and renal profiles and histopathological changes. Sci Rep 14:5682","journal-title":"Sci Rep"},{"key":"2193_CR5","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1021\/acs.molpharmaceut.6b00248","volume":"13","author":"A Aliper","year":"2016","unstructured":"Aliper A, Plis S, Artemov A, Ulloa A, Mamoshina P, Zhavoronkov A (2016) Deep learning applications for predicting pharmacological properties of drugs and drug repurposing using transcriptomic data. Mol Pharm 13:2524\u20132530","journal-title":"Mol Pharm"},{"key":"2193_CR6","doi-asserted-by":"publisher","first-page":"17810","DOI":"10.1038\/s41598-021-97160-3","volume":"11","author":"C Ambrus","year":"2021","unstructured":"Ambrus C, Bakos \u00c9, Sarkadi B, \u00d6zvegy-Laczka C, Telbisz \u00c1 (2021) Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics. Sci Rep 11:17810","journal-title":"Sci Rep"},{"key":"2193_CR7","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1016\/j.drudis.2021.07.026","volume":"26","author":"I Aronskyy","year":"2021","unstructured":"Aronskyy I, Masoudi-Sobhanzadeh Y, Cappuccio A, Zaslavsky E (2021) Advances in the computational landscape for repurposed drugs against COVID-19. Drug Discovery Today 26:2800\u20132815","journal-title":"Drug Discovery Today"},{"key":"2193_CR8","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1016\/j.drudis.2022.05.013","volume":"27","author":"N Arul Murugan","year":"2022","unstructured":"Arul Murugan N, Ruba Priya G, Narahari Sastry G, Markidis S (2022) Artificial intelligence in virtual screening: models versus experiments. Drug Discovery Today 27:1913\u20131923","journal-title":"Drug Discovery Today"},{"key":"2193_CR9","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.3390\/microorganisms10081639","volume":"10","author":"F Assmus","year":"2022","unstructured":"Assmus F, Driouich JS, Abdelnabi R, Vangeel L, Touret F, Adehin A, Chotsiri P, Cochin M, Foo CS, Jochmans D, Kim S, Luciani L, Moureau G, Park S, P\u00e9tit PR, Shum D, Wattanakul T, Weynand B, Fraisse L, Ioset JR, Mowbray CE, Owen A, Hoglund RM, Tarning J, Lamballerie X, Nougair\u00e8de A, Neyts J, Sj\u00f6 P, Escudi\u00e9 F, Scandale I, Chatelain E (2022) Need for a standardized translational drug development platform: lessons learned from the repurposing of drugs for COVID-19. Microorganisms 10:1639","journal-title":"Microorganisms"},{"key":"2193_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/bmb\/ldac037","volume":"147","author":"Y Augustin","year":"2023","unstructured":"Augustin Y, Staines HM, Velavan TP, Kamarulzaman A, Kremsner PG, Krishna S (2023) Drug repurposing for COVID-19: current evidence from randomized controlled adaptive platform trials and living systematic reviews. Br Med Bull 147:31\u201349","journal-title":"Br Med Bull"},{"key":"2193_CR11","first-page":"21","volume-title":"Bioactive molecule prediction using extreme gradient boosting","author":"I Babajide Mustapha","year":"2016","unstructured":"Babajide Mustapha I, Saeed F (2016) Bioactive molecule prediction using extreme gradient boosting. Molecules, Basel, Switzerland, p 21"},{"key":"2193_CR12","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/bcp.14358","volume":"87","author":"D Back","year":"2021","unstructured":"Back D, Marzolini C, Hodge C, Marra F, Boyle A, Gibbons S, Burger D, Khoo S (2021) COVID-19 treatment in patients with comorbidities: awareness of drug-drug interactions. Br J Clin Pharmacol 87:212\u2013213","journal-title":"Br J Clin Pharmacol"},{"key":"2193_CR13","doi-asserted-by":"publisher","first-page":"123560","DOI":"10.1016\/j.eswa.2024.123560","volume":"249","author":"C Bansal","year":"2024","unstructured":"Bansal C, Deepa P, Agarwal V, Chandra R (2024) A clustering and graph deep learning-based framework for COVID-19 drug repurposing. Expert Syst Appl 249:123560","journal-title":"Expert Syst Appl"},{"key":"2193_CR14","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1111\/bcp.14630","volume":"87","author":"JS Barrett","year":"2021","unstructured":"Barrett JS (2021) Risk assessment of therapeutic agents under consideration to treat COVID-19 in paediatric patients and pregnant women. Br J Clin Pharmacol 87:3462\u20133480","journal-title":"Br J Clin Pharmacol"},{"key":"2193_CR15","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1093\/cid\/ciab880","volume":"74","author":"A Bhimraj","year":"2022","unstructured":"Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, Edwards KM, Gandhi RT, Gallagher JC, Muller WJ, O\u2019Horo JC, Shoham S, Wollins DS, Falck-Ytter Y (2022) Therapeutic Emergency Use Authorizations (EUAs) During Pandemics: Double-edged Swords. Clin Infect diseases: official publication Infect Dis Soc Am 74:1686\u20131690","journal-title":"Clin Infect diseases: official publication Infect Dis Soc Am"},{"key":"2193_CR16","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1111\/bcp.14026","volume":"85","author":"AM Breckenridge","year":"2019","unstructured":"Breckenridge AM, Breckenridge RA, Peck CC (2019) Report on the current status of the use of real-world data (RWD) and real-world evidence (RWE) in drug development and regulation. Br J Clin Pharmacol 85:1874\u20131877","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"2193_CR17","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.3390\/ph18111649","volume":"18","author":"H Calvo","year":"2025","unstructured":"Calvo H, Islas-D\u00edaz D, Hern\u00e1ndez-Laureano E (2025) Pattern recognition algorithms in pharmacogenomics and drug repurposing\u2014case study: ribavirin and lopinavir. Pharmaceuticals 18(11):1649","journal-title":"Pharmaceuticals"},{"key":"2193_CR18","doi-asserted-by":"publisher","first-page":"704205","DOI":"10.3389\/fphar.2021.704205","volume":"12","author":"C Chakraborty","year":"2021","unstructured":"Chakraborty C, Sharma AR, Bhattacharya M, Agoramoorthy G, Lee SS (2021) The drug repurposing for COVID-19 clinical trials provide very effective therapeutic combinations: lessons learned from major clinical studies. Front Pharmacol 12:704205","journal-title":"Front Pharmacol"},{"key":"2193_CR19","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.2217\/fmb.15.105","volume":"10","author":"CY Chan","year":"2015","unstructured":"Chan CY, Ooi EE (2015) Dengue: an update on treatment options. Future Microbiol 10:2017\u20132031","journal-title":"Future Microbiol"},{"key":"2193_CR20","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s41401-024-01382-w","volume":"46","author":"E Chen","year":"2025","unstructured":"Chen E, Xi L (2025) Cardiovascular adverse effects of antiviral therapies for COVID-19: evidence and plausible mechanisms. Acta Pharmacol Sin 46:554\u2013564","journal-title":"Acta Pharmacol Sin"},{"key":"2193_CR21","doi-asserted-by":"publisher","first-page":"12426","DOI":"10.3390\/ijms252212426","volume":"25","author":"WK Cho","year":"2024","unstructured":"Cho WK, Choi HJ, Ahmad SS, Choi I, Ma JY (2024) Antiviral effect of amentoflavone against influenza viruses. Int J Mol Sci 25:12426","journal-title":"Int J Mol Sci"},{"key":"2193_CR22","doi-asserted-by":"crossref","unstructured":"Chu JJH (2023) Pandemic preparedness: the Singapore drug repurposing antiviral strategy. RExPO23. REPO4EU, Stockholm, Sweden","DOI":"10.58647\/REXPO.23003"},{"key":"2193_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1089\/omi.2022.0068","volume":"26","author":"Y Cong","year":"2022","unstructured":"Cong Y, Endo T (2022) Multi-omics and artificial intelligence-guided drug repositioning: prospects, challenges, and lessons learned from COVID-19. OMICS 26:361\u2013371","journal-title":"OMICS"},{"key":"2193_CR24","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.2174\/0929867327666200416131117","volume":"27","author":"M Costanzo","year":"2020","unstructured":"Costanzo M, De Giglio MAR, Roviello GN (2020) SARS-CoV-2: Recent Reports on antiviral therapies based on lopinavir\/ritonavir, darunavir\/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus. Curr Med Chem 27:4536\u20134541","journal-title":"Curr Med Chem"},{"key":"2193_CR56","doi-asserted-by":"publisher","first-page":"107945","DOI":"10.1016\/j.asoc.2021.107945","volume":"113","author":"K Deepthi","year":"2021","unstructured":"Deepthi K, and Jereesh AS (2021) A deep learning ensemble approach to prioritize antiviral drugs against novel coronavirus SARS-CoV-2 for COVID-19 drug repurposing. Appl Soft Comput 113:107945","journal-title":"Appl Soft Comput"},{"key":"2193_CR25","doi-asserted-by":"publisher","first-page":"e0122622","DOI":"10.1128\/aac.01226-22","volume":"66","author":"CE DeLaurentis","year":"2022","unstructured":"DeLaurentis CE, Kiser J, Zucker J (2022) New perspectives on antimicrobial agents: tecovirimat for treatment of human monkeypox virus. antimicrob agents Chemother 66:e0122622","journal-title":"Antimicrob Agents Chemother"},{"key":"2193_CR26","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/qjmed\/hcab247","volume":"114","author":"J Deng","year":"2021","unstructured":"Deng J, Zhou F, Ali S, Heybati K, Hou W, Huang E, Wong CY (2021) Efficacy and safety of ivermectin for the treatment of COVID-19: a systematic review and meta-analysis. QJM: monthly J Association Physicians 114:721\u2013732","journal-title":"QJM: monthly J Association Physicians"},{"key":"2193_CR27","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1021\/acsinfecdis.3c00311","volume":"9","author":"S Deshpande","year":"2023","unstructured":"Deshpande S, Huo W, Shrestha R, Sparrow K, Wood JM, Evans GB, Harris LD, Kingston RL, Bulloch EMM (2023) Galidesivir triphosphate promotes stalling of dengue-2 virus polymerase immediately prior to incorporation. ACS Infect Dis 9:1658\u20131673","journal-title":"ACS Infect Dis"},{"key":"2193_CR28","doi-asserted-by":"publisher","first-page":"36858","DOI":"10.1021\/acsomega.4c05357","volume":"9","author":"TL Devi","year":"2024","unstructured":"Devi TL, Devi MM, Okram M, Singh OM (2024) Repurposed drugs during the outbreak of pandemic COVID-19: a mini-review on their molecular structures and hit-and-trial results. ACS omega 9:36858\u201336864","journal-title":"ACS omega"},{"key":"2193_CR29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/v17020163","volume":"17","author":"L Di Marco","year":"2025","unstructured":"Di Marco L, Cannova S, Ferrigno E, Landro G, Nonni R, Mantia C, Cartabellotta F, Calvaruso V, Di Marco V (2025) A comprehensive review of antiviral therapy for hepatitis C: the long journey from interferon to pan-genotypic direct-acting antivirals (DAAs). Viruses 17:163","journal-title":"Viruses"},{"key":"2193_CR30","doi-asserted-by":"publisher","first-page":"598313","DOI":"10.3389\/fvets.2020.598313","volume":"7","author":"Z Dong","year":"2020","unstructured":"Dong Z, Xing SY, Zhang JY, Zhou XZ (2020) 14-Day repeated intraperitoneal toxicity test of ivermectin microemulsion injection in wistar rats. Front veterinary Sci 7:598313","journal-title":"Front veterinary Sci"},{"key":"2193_CR31","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.2174\/0929867327666200812215852","volume":"28","author":"IJ Dos Santos Nascimento","year":"2021","unstructured":"Dos Santos Nascimento IJ, de Aquino TM, da Silva-J\u00fanior EF (2021) Drug repurposing: a strategy for discovering inhibitors against emerging viral infections. Curr Med Chem 28:2887\u20132942","journal-title":"Curr Med Chem"},{"key":"2193_CR32","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/S0140-6736(22)00454-8","volume":"399","author":"RA Dwek","year":"2022","unstructured":"Dwek RA, Bell JI, Feldmann M, Zitzmann N (2022) Host-targeting oral antiviral drugs to prevent pandemics. Lancet (London England) 399:1381\u20131382","journal-title":"Lancet (London England)"},{"key":"2193_CR33","doi-asserted-by":"publisher","first-page":"107536","DOI":"10.1016\/j.compbiolchem.2021.107536","volume":"93","author":"H El-Behery","year":"2021","unstructured":"El-Behery H, Attia AF, El-Feshawy N, Torkey H (2021) Efficient machine learning model for predicting drug-target interactions with case study for Covid-19. Comput Biol Chem 93:107536","journal-title":"Comput Biol Chem"},{"key":"2193_CR34","first-page":"e85033","volume":"17","author":"KW Elechi","year":"2025","unstructured":"Elechi KW, Adeoye AF, Olaniyi AO, Akanbi OO, Olumeko I, Udensi CG, Kolapo TJ, Barrah VU (2025) Translational success and pharmacoeconomic lessons of pandemic-driven drug repurposing. Cureus 17:e85033","journal-title":"Cureus"},{"key":"2193_CR35","doi-asserted-by":"publisher","first-page":"1182465","DOI":"10.3389\/fphar.2023.1182465","volume":"14","author":"M Elkashlan","year":"2023","unstructured":"Elkashlan M, Ahmad RM, Hajar M, Al Jasmi F, Corchado JM, Nasarudin NA, Mohamad MS (2023) A review of SARS-CoV-2 drug repurposing: databases and machine learning models. Front Pharmacol 14:1182465","journal-title":"Front Pharmacol"},{"key":"2193_CR36","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3390\/biom14080911","volume":"14","author":"J Elste","year":"2024","unstructured":"Elste J, Saini A, Mejia-Alvarez R, Mej\u00eda A, Mill\u00e1n-Pacheco C, Swanson-Mungerson M, Tiwari V (2024) Significance of artificial intelligence in the study of virus-host cell interactions. Biomolecules 14:911","journal-title":"Biomolecules"},{"key":"2193_CR37","doi-asserted-by":"publisher","first-page":"23889","DOI":"10.1021\/acsomega.5c00549","volume":"10","author":"FJN Ferreira","year":"2025","unstructured":"Ferreira FJN, Carneiro AS (2025) AI-driven drug discovery: a comprehensive review. ACS omega 10:23889\u201323903","journal-title":"ACS omega"},{"key":"2193_CR38","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.virusres.2019.02.011","volume":"264","author":"M Garc\u00eda-Serradilla","year":"2019","unstructured":"Garc\u00eda-Serradilla M, Risco C, Pacheco B (2019) Drug repurposing for new, efficient, broad spectrum antivirals. Virus Res 264:22\u201331","journal-title":"Virus Res"},{"key":"2193_CR39","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/v16010045","volume":"16","author":"S Gautam","year":"2023","unstructured":"Gautam S, Thakur A, Rajput A, Kumar M (2023) Anti-dengue: a machine learning-assisted prediction of small molecule antivirals against dengue virus and implications in drug repurposing. Viruses 16:45","journal-title":"Viruses"},{"key":"2193_CR40","doi-asserted-by":"publisher","first-page":"13840","DOI":"10.1021\/acsomega.3c00030","volume":"8","author":"N Ghosh","year":"2023","unstructured":"Ghosh N, Saha I, Gambin A (2023) Interactome-based machine learning predicts potential therapeutics for COVID-19. ACS omega 8:13840\u201313854","journal-title":"ACS omega"},{"key":"2193_CR41","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1006\/faat.1996.0117","volume":"32","author":"JA Greene","year":"1996","unstructured":"Greene JA, Ayers KM, Tucker WE Jr., de Miranda P (1996) Nonclinical toxicology studies with zidovudine: reproductive toxicity studies in rats and rabbits. Fundamental Appl toxicology: official J Soc Toxicol 32:140\u2013147","journal-title":"Fundamental Appl toxicology: official J Soc Toxicol"},{"key":"2193_CR42","doi-asserted-by":"publisher","first-page":"100070","DOI":"10.1016\/j.aichem.2024.100070","volume":"2","author":"S Guan","year":"2024","unstructured":"Guan S, Wang G (2024) Drug discovery and development in the era of artificial intelligence: From machine learning to large language models. Artif Intell Chem 2:100070","journal-title":"Artif Intell Chem"},{"key":"2193_CR43","doi-asserted-by":"publisher","first-page":"102399","DOI":"10.1016\/j.xcrm.2025.102399","volume":"6","author":"C Guo","year":"2025","unstructured":"Guo C, Gao T, Xue B, Zhang L, Wang S, Xiao R, Kong L, Zhang Y, Xin Q, Cao Y, Gu X, Jiang C, Wu J (2025) In situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence. Cell Rep Med 6:102399","journal-title":"Cell Rep Med"},{"key":"2193_CR44","doi-asserted-by":"publisher","first-page":"1700111","DOI":"10.1002\/minf.201700111","volume":"37","author":"A Gupta","year":"2018","unstructured":"Gupta A, M\u00fcller AT, Huisman BJH, Fuchs JA, Schneider P, Schneider G (2018) Generative recurrent networks for de novo drug design. Mol Inf 37:1700111","journal-title":"Mol Inf"},{"key":"2193_CR45","doi-asserted-by":"publisher","first-page":"e0121023","DOI":"10.1128\/aac.01210-23","volume":"68","author":"S Haid","year":"2024","unstructured":"Haid S, Matthaei A, Winkler M, Sake SM, Gunesch AP, Milke V, K\u00f6hler NM, R\u00fcckert J, Vieyres G, K\u00fchl D, Nguyen TT, G\u00f6hl M, Lasswitz L, Zapatero-Belinch\u00f3n FJ, Brogden G, Gerold G, Wiegmann B, Bilitewski U, Brown RJP, Br\u00f6nstrup M, Schulz TF, Pietschmann T (2024) Repurposing screen identifies novel candidates for broad-spectrum coronavirus antivirals and druggable host targets. Antimicrob Agents Chemother 68:e0121023","journal-title":"Antimicrob Agents Chemother"},{"key":"2193_CR46","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.3201\/eid1511.090720","volume":"15","author":"DM Hartley","year":"2009","unstructured":"Hartley DM, Nelson NP, Perencevich EN (2009) Antiviral drugs for treatment of patients infected with pandemic (H1N1) 2009 virus. Emerg Infect Dis 15:1851\u20131852","journal-title":"Emerg Infect Dis"},{"key":"2193_CR47","doi-asserted-by":"publisher","first-page":"116069","DOI":"10.1016\/j.ejmech.2023.116069","volume":"265","author":"Y He","year":"2024","unstructured":"He Y, Zhou J, Gao H, Liu C, Zhan P, Liu X (2024) Broad-spectrum antiviral strategy: Host-targeting antivirals against emerging and re-emerging viruses. Eur J Med Chem 265:116069","journal-title":"Eur J Med Chem"},{"key":"2193_CR48","doi-asserted-by":"crossref","unstructured":"Hsieh K, Wang Y, Chen L, Zhao Z, Savitz S, Jiang X, Tang J, Kim Y (2020) Drug Repurposing for COVID-19 using Graph neural network with genetic, mechanistic, and epidemiological validation. Res Sq","DOI":"10.21203\/rs.3.rs-114758\/v1"},{"key":"2193_CR49","doi-asserted-by":"publisher","first-page":"23179","DOI":"10.1038\/s41598-021-02353-5","volume":"11","author":"K Hsieh","year":"2021","unstructured":"Hsieh K, Wang Y, Chen L, Zhao Z, Savitz S, Jiang X, Tang J, Kim Y (2021) Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence. Sci Rep 11:23179","journal-title":"Sci Rep"},{"key":"2193_CR50","doi-asserted-by":"crossref","unstructured":"Hsieh K, Wang Y, Chen L, Zhao Z, Savitz S, Jiang X, Tang J, Kim Y (2022) Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence. ArXiv","DOI":"10.1038\/s41598-021-02353-5"},{"key":"2193_CR51","first-page":"2326","volume":"13","author":"CW Hsu","year":"2023","unstructured":"Hsu CW, Yang WW, Hou CY, Feng IJ, Huang TY, Lee PL, Guo HR, Huang CY, Su SB (2023) Patients with hepatitis C undergoing direct-acting antiviral treatment have a lower SARS-CoV-2 infection rate. Life (Basel Switzerland) 13:2326","journal-title":"Life (Basel Switzerland)"},{"key":"2193_CR52","doi-asserted-by":"crossref","unstructured":"Immerheiser M, Zimniak M, Hilpert H, Geiger N, K\u00f6nig E-M, Bodem J (2021) Towards a broad-spectrum antiviral, the myristoyltransferase inhibitor IMP-1088 suppresses viral replication\u2013the yellow fever NS5 is myristoylated. bioRxiv","DOI":"10.1101\/2021.03.09.434547"},{"key":"2193_CR53","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1097\/01.NPR.0000000000000025","volume":"48","author":"L Jarrell","year":"2023","unstructured":"Jarrell L, Perryman K (2023) Mpox (monkeypox): diagnosis, prevention, and management in adults. The Nurse Practitioner 48:13\u201320","journal-title":"The Nurse Practitioner"},{"key":"2193_CR54","doi-asserted-by":"crossref","unstructured":"Jiao Q, Qiu Z, Wang Y, Chen C, Yang Z, Cui X (2021) Edge-gated graph neural network for predicting protein-ligand binding affinities. In: 2021 IEEE international conference on bioinformatics and biomedicine (BIBM). IEEE. pp 334\u2013339","DOI":"10.1109\/BIBM52615.2021.9669846"},{"key":"2193_CR55","doi-asserted-by":"publisher","first-page":"e2100190","DOI":"10.1002\/minf.202100190","volume":"41","author":"L John","year":"2022","unstructured":"John L, Soujanya Y, Mahanta HJ, Narahari Sastry G (2022) Chemoinformatics and machine learning approaches for identifying antiviral compounds. Mol Inf 41:e2100190","journal-title":"Mol Inf"},{"key":"2193_CR57","doi-asserted-by":"publisher","first-page":"e170236","DOI":"10.1172\/JCI170236","volume":"133","author":"M Karim","year":"2023","unstructured":"Karim M, Lo CW, Einav S (2023) Preparing for the next viral threat with broad-spectrum antivirals. J Clin Investig 133:e170236","journal-title":"J Clin Investig"},{"key":"2193_CR58","doi-asserted-by":"publisher","first-page":"66","DOI":"10.18231\/j.jpbs.2023.011","volume":"11","author":"S Khan","year":"2023","unstructured":"Khan S, Agnihotri J, Patil S, Khan N (2023) Drug repurposing: a futuristic approach in drug discovery. J Pharm Biol Sci 11:66\u201369","journal-title":"J Pharm Biol Sci"},{"key":"2193_CR59","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/bdr2.2111","volume":"115","author":"L Kirkwood-Johnson","year":"2023","unstructured":"Kirkwood-Johnson L, Marikawa Y (2023) Developmental toxicity of remdesivir, an anti-COVID-19 drug, is implicated by in vitro assays using morphogenetic embryoid bodies of mouse and human pluripotent stem cells. Birth defects Res 115:224\u2013239","journal-title":"Birth defects Res"},{"key":"2193_CR60","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/s41598-023-27636-x","volume":"13","author":"K K\u00f6chl","year":"2023","unstructured":"K\u00f6chl K, Schopper T, Durmaz V, Parigger L, Singh A, Krassnigg A, Cespugli M, Wu W, Yang X, Zhang Y, Wang WW, Selluski C, Zhao T, Zhang X, Bai C, Lin L, Hu Y, Xie Z, Zhang Z, Yan J, Zatloukal K, Gruber K, Steinkellner G, Gruber CC (2023) Optimizing variant-specific therapeutic SARS-CoV-2 decoys using deep-learning-guided molecular dynamics simulations. Sci Rep 13:774","journal-title":"Sci Rep"},{"key":"2193_CR61","doi-asserted-by":"crossref","unstructured":"Kotkondawar RR, Sutar SR, Kiwelekar AW, Kadam VJ (2024) Integrating transformer-based language model for drug discovery. In: 2024 11th international conference on computing for sustainable global development (INDIACom). IEEE. pp 1096\u20131101","DOI":"10.23919\/INDIACom61295.2024.10498263"},{"key":"2193_CR62","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1186\/s12913-022-08272-z","volume":"22","author":"N Krishnamurthy","year":"2022","unstructured":"Krishnamurthy N, Grimshaw AA, Axson SA, Choe SH, Miller JE (2022) Drug repurposing: a systematic review on root causes, barriers and facilitators. BMC Health Serv Res 22:970","journal-title":"BMC Health Serv Res"},{"key":"2193_CR63","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.coi.2013.08.004","volume":"25","author":"GL Law","year":"2013","unstructured":"Law GL, Tisoncik-Go J, Korth MJ, Katze MG (2013) Drug repurposing: a better approach for infectious disease drug discovery? Curr Opin Immunol 25:588\u2013592","journal-title":"Curr Opin Immunol"},{"key":"2193_CR64","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3390\/v15030705","volume":"15","author":"MF Lee","year":"2023","unstructured":"Lee MF, Wu YS, Poh CL (2023) Molecular mechanisms of antiviral agents against dengue virus. Viruses 15:705","journal-title":"Viruses"},{"key":"2193_CR65","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.00394-19","volume":"63","author":"C Li","year":"2019","unstructured":"Li C, Zu S, Deng YQ, Li D, Parvatiyar K, Quanquin N, Shang J, Sun N, Su J, Liu Z, Wang M, Aliyari SR, Li XF, Wu A, Ma F, Shi Y, Nielsevn-Saines K, Jung JU, Qin FX, Qin CF, Cheng G (2019a) Azithromycin protects against Zika virus infection by upregulating virus-induced type I and III interferon responses. Antimicrob Agents Chemother 63:10\u20131128","journal-title":"Antimicrob Agents Chemother"},{"key":"2193_CR66","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.drudis.2019.01.018","volume":"24","author":"CC Li","year":"2019","unstructured":"Li CC, Wang XJ, Wang HR (2019b) Repurposing host-based therapeutics to control coronavirus and influenza virus. Drug Discovery Today 24:726\u2013736","journal-title":"Drug Discovery Today"},{"key":"2193_CR67","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","volume":"22","author":"G Li","year":"2023","unstructured":"Li G, Hilgenfeld R, Whitley R, De Clercq E (2023) Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discovery 22:449\u2013475","journal-title":"Nat Rev Drug Discovery"},{"key":"2193_CR68","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jhep.2019.06.002","volume":"71","author":"J Llaneras","year":"2019","unstructured":"Llaneras J, Riveiro-Barciela M, Lens S, Diago M, Cachero A, Garc\u00eda-Samaniego J, Conde I, Arencibia A, Arenas J, Gea F, Torras X, Luis Calleja J, Antonio Carri\u00f3n J, Fern\u00e1ndez I, Mar\u00eda Morillas R, Rosales JM, Carmona I, Fern\u00e1ndez-Rodr\u00edguez C, Hern\u00e1ndez-Guerra M, Llerena S, Bernal V, Turnes J, Gonz\u00e1lez-Santiago JM, Montoliu S, Figueruela B, Badia E, Delgado M, Fern\u00e1ndez-Bermejo M, I\u00f1arrairaegui M, Pascasio JM, Esteban R, Mari\u00f1o Z, Buti M (2019) Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. J Hepatol 71:666\u2013672","journal-title":"J Hepatol"},{"issue":"9","key":"2193_CR70","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.3390\/v12091058","volume":"12","author":"ZY Low","year":"2020","unstructured":"Low ZY, Farouk IA, Lal SK (2020) Drug repositioning: new approaches and future prospects for life-debilitating diseases and the COVID-19 pandemic outbreak. Viruses 12(9):1058","journal-title":"Viruses"},{"key":"2193_CR69","doi-asserted-by":"publisher","first-page":"21221","DOI":"10.1038\/s41598-021-98949-y","volume":"11","author":"ZX Low","year":"2021","unstructured":"Low ZX, OuYong BM, Hassandarvish P, Poh CL, Ramanathan B (2021) Antiviral activity of silymarin and baicalein against dengue virus. Sci Rep 11:21221","journal-title":"Sci Rep"},{"key":"2193_CR71","doi-asserted-by":"publisher","first-page":"bbab320","DOI":"10.1093\/bib\/bbab320","volume":"22","author":"H Lv","year":"2021","unstructured":"Lv H, Shi L, Berkenpas JW, Dao FY, Zulfiqar H, Ding H, Zhang Y, Yang L, Cao R (2021) Application of artificial intelligence and machine learning for COVID-19 drug discovery and vaccine design. Brief Bioinform 22:bbab320","journal-title":"Brief Bioinform"},{"key":"2193_CR72","doi-asserted-by":"publisher","first-page":"117","DOI":"10.5530\/jyp.2019.11.26","volume":"11","author":"D Mani","year":"2019","unstructured":"Mani D, Wadhwani A, Krishnamurthy PT (2019) Drug repurposing in antiviral research: a current scenario. J Young Pharmacists 11:117","journal-title":"J Young Pharmacists"},{"key":"2193_CR73","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40268-020-00333-0","volume":"21","author":"F Marra","year":"2021","unstructured":"Marra F, Smolders EJ, El-Sherif O, Boyle A, Davidson K, Sommerville AJ, Marzolini C, Siccardi M, Burger D, Gibbons S, Khoo S, Back D (2021) Recommendations for dosing of repurposed COVID-19 medications in patients with renal and hepatic impairment. Drugs R D 21:9\u201327","journal-title":"Drugs R D"},{"issue":"7","key":"2193_CR74","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.3390\/v15071508","volume":"15","author":"DE Martin","year":"2023","unstructured":"Martin DE, Pandey N, Chavda P, Singh G, Sutariya R, Sancilio F, Tripp RA (2023) Oral Probenecid for nonhospitalized adults with symptomatic mild-to-moderate COVID-19. Viruses 15(7):1508","journal-title":"Viruses"},{"key":"2193_CR75","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40656-022-00532-9","volume":"44","author":"M Maziarz","year":"2022","unstructured":"Maziarz M, Stencel A (2022) The failure of drug repurposing for COVID-19 as an effect of excessive hypothesis testing and weak mechanistic evidence. Hist Philos Life Sci 44:47","journal-title":"Hist Philos Life Sci"},{"key":"2193_CR76","doi-asserted-by":"publisher","first-page":"104490","DOI":"10.1016\/j.bioorg.2020.104490","volume":"106","author":"K Mohamed","year":"2021","unstructured":"Mohamed K, Yazdanpanah N, Saghazadeh A, Rezaei N (2021) Computational drug discovery and repurposing for the treatment of COVID-19: a systematic review. Bioorg Chem 106:104490","journal-title":"Bioorg Chem"},{"key":"2193_CR77","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.dsx.2020.06.068","volume":"14","author":"S Mohanty","year":"2020","unstructured":"Mohanty S, Harun Ai Rashid M, Mridul M, Mohanty C, Swayamsiddha S (2020) Application of artificial intelligence in COVID-19 drug repurposing. Diabetes metabolic syndrome 14:1027\u20131031","journal-title":"Diabetes metabolic syndrome"},{"key":"2193_CR78","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/13102818.2020.1775118","volume":"34","author":"G Momekov","year":"2020","unstructured":"Momekov G, Momekova D (2020) Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens. Biotechnol Biotechnol Equip 34:469\u2013474","journal-title":"Biotechnol Biotechnol Equip"},{"key":"2193_CR79","doi-asserted-by":"publisher","first-page":"e2025581118","DOI":"10.1073\/pnas.2025581118","volume":"118","author":"D do Morselli Gysi","year":"2021","unstructured":"Morselli Gysi D, do Valle \u00cd, Zitnik M, Ameli A, Gan X, Varol O, Ghiassian SD, Patten JJ, Davey RA, Loscalzo J, Barab\u00e1si AL (2021) Network medicine framework for identifying drug-repurposing opportunities for COVID-19. Proc Natl Acad Sci USA 118:e2025581118","journal-title":"Proc Natl Acad Sci USA"},{"key":"2193_CR80","doi-asserted-by":"publisher","first-page":"107930","DOI":"10.1016\/j.pharmthera.2021.107930","volume":"228","author":"YL Ng","year":"2021","unstructured":"Ng YL, Salim CK, Chu JJH (2021) Drug repurposing for COVID-19: approaches, challenges and promising candidates. Pharmacol Ther 228:107930","journal-title":"Pharmacol Ther"},{"key":"2193_CR81","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/j.drudis.2022.04.001","volume":"27","author":"DK Ngan","year":"2022","unstructured":"Ngan DK, Xu T, Xia M, Zheng W, Huang R (2022) Repurposing drugs as COVID-19 therapies: a toxicity evaluation. Drug Discovery Today 27:1983\u20131993","journal-title":"Drug Discovery Today"},{"key":"2193_CR82","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3390\/ph15060765","volume":"15","author":"MW Nicholson","year":"2022","unstructured":"Nicholson MW, Huang CY, Wang JY, Ting CY, Cheng YC, Chan DZH, Lee YC, Hsu CC, Hsu YH, Chang CMC, Hsieh ML, Cheng YY, Lin YL, Chen CH, Wu YT, Hacker TA, Wu JC, Kamp TJ, Hsieh PCH (2022) Cardio- and neurotoxicity of selected anti-COVID-19 drugs. Pharmaceuticals (Basel Switzerland) 15:765","journal-title":"Pharmaceuticals (Basel Switzerland)"},{"key":"2193_CR83","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/s41598-025-31048-4","volume":"16","author":"O Ozhan","year":"2026","unstructured":"Ozhan O, Yildiz A, Bakar B, Ulu A, Kucukakcali Z, Karaca E, Vardi N, Ates B, Parlakpinar H (2026) Evaluation of the cardiopulmonary effects of repurposed COVID-19 therapeutics in healthy rats. Sci Rep 16:1770","journal-title":"Sci Rep"},{"key":"2193_CR84","doi-asserted-by":"publisher","first-page":"e1597","DOI":"10.1002\/wcms.1597","volume":"12","author":"X Pan","year":"2022","unstructured":"Pan X, Lin X, Cao D, Zeng X, Yu PS, He L, Nussinov R, Cheng F (2022) Deep learning for drug repurposing: methods, databases, and applications. Wiley Interdiscip Rev Comput Mol Sci 12:e1597","journal-title":"Wiley Interdiscip Rev Comput Mol Sci"},{"key":"2193_CR85","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1111\/bph.15204","volume":"177","author":"SL Penman","year":"2020","unstructured":"Penman SL, Kiy RT, Jensen RL, Beoku-Betts C, Alfirevic A, Back D, Khoo SH, Owen A, Pirmohamed M, Park BK, Meng X, Goldring CE, Chadwick AE (2020) Safety perspectives on presently considered drugs for the treatment of COVID-19. Br J Pharmacol 177:4353\u20134374","journal-title":"Br J Pharmacol"},{"key":"2193_CR86","doi-asserted-by":"publisher","first-page":"1460100","DOI":"10.3389\/fddsv.2024.1460100","volume":"4","author":"L Pinzi","year":"2024","unstructured":"Pinzi L, Bisi N, Rastelli G (2024) How drug repurposing can advance drug discovery: challenges and opportunities. Front Drug Discov 4:1460100","journal-title":"Front Drug Discov"},{"key":"2193_CR87","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.drudis.2018.11.022","volume":"24","author":"P Polamreddy","year":"2019","unstructured":"Polamreddy P, Gattu N (2019) The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions. Drug Discovery Today 24:789\u2013795","journal-title":"Drug Discovery Today"},{"key":"2193_CR88","doi-asserted-by":"publisher","first-page":"e01164","DOI":"10.1002\/prp2.1164","volume":"12","author":"F Pourkarim","year":"2024","unstructured":"Pourkarim F, Entezari-Maleki T (2024) Clinical considerations on monkeypox antiviral medications: an overview. Pharmacol Res Perspect 12:e01164","journal-title":"Pharmacol Res Perspect"},{"key":"2193_CR89","doi-asserted-by":"publisher","first-page":"100042","DOI":"10.1016\/j.crphar.2021.100042","volume":"2","author":"K Prasad","year":"2021","unstructured":"Prasad K, Kumar V (2021) Artificial intelligence-driven drug repurposing and structural biology for SARS-CoV-2. Curr Res Pharmacol drug discovery 2:100042","journal-title":"Curr Res Pharmacol drug discovery"},{"key":"2193_CR90","doi-asserted-by":"publisher","first-page":"e1010662","DOI":"10.1371\/journal.ppat.1010662","volume":"18","author":"L Priyamvada","year":"2022","unstructured":"Priyamvada L, Kallemeijn WW, Faronato M, Wilkins K, Goldsmith CS, Cotter CA, Ojeda S, Solari R, Moss B, Tate EW, Satheshkumar PS (2022) Inhibition of vaccinia virus L1 N-myristoylation by the host N-myristoyltransferase inhibitor IMP-1088 generates non-infectious virions defective in cell entry. PLoS Pathog 18:e1010662","journal-title":"PLoS Pathog"},{"key":"2193_CR91","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3390\/toxics11100875","volume":"11","author":"M Rao","year":"2023","unstructured":"Rao M, McDuffie E, Sachs C (2023) Artificial intelligence\/machine learning-driven small molecule repurposing via off-target prediction and transcriptomics. Toxics 11:875","journal-title":"Toxics"},{"key":"2193_CR92","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1039\/C9SC03414E","volume":"11","author":"AS Rifaioglu","year":"2020","unstructured":"Rifaioglu AS, Nalbat E, Atalay V, Martin MJ, Cetin-Atalay R, Do\u011fan T (2020) DEEPScreen: high performance drug-target interaction prediction with convolutional neural networks using 2-D structural compound representations. Chem Sci 11:2531\u20132557","journal-title":"Chem Sci"},{"key":"2193_CR93","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1109\/TMI.2022.3178523","volume":"41","author":"MS Saberian","year":"2022","unstructured":"Saberian MS, Moriarty KP, Olmstead AD, Hallgrimson C, Jean F, Nabi IR, Libbrecht MW, Hamarneh G (2022) DEEMD: Drug Efficacy Estimation Against SARS-CoV-2 Based on Cell Morphology With Deep Multiple Instance Learning. IEEE Trans Med Imaging 41:3128\u20133145","journal-title":"IEEE Trans Med Imaging"},{"key":"2193_CR94","first-page":"280","volume":"96","author":"AU Sabitov","year":"2024","unstructured":"Sabitov AU, Lioznov DA, Zhdanov KV, Tihonova EP, Esaulenko EV, Sorokin PV (2024) [Results of a randomized double-blind multicenter clinical trial of the efficacy and safety of the drug riamilovir for the prevention of COVID-19]. Ter Arkh 96:280\u2013285","journal-title":"Ter Arkh"},{"key":"2193_CR95","doi-asserted-by":"publisher","first-page":"12","DOI":"10.9734\/jamps\/2024\/v26i12728","volume":"26","author":"G Saini","year":"2024","unstructured":"Saini G, Kumar I, Verma KK (2024) The potential of drug repurposing as a rapid response strategy in COVID-19 therapeutics. J Adv Med Pharm Sci 26:12\u201331","journal-title":"J Adv Med Pharm Sci"},{"key":"2193_CR96","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s12939-025-02598-w","volume":"24","author":"N Sakis","year":"2025","unstructured":"Sakis N, Slone M, Michaan N, Ben-Eliyahu S (2025) Advancing the human right to health in cancer care through drug repurposing strategies. Int J Equity Health 24:227","journal-title":"Int J Equity Health"},{"key":"2193_CR97","doi-asserted-by":"publisher","first-page":"114521","DOI":"10.1016\/j.intimp.2025.114521","volume":"153","author":"S Sarvepalli","year":"2025","unstructured":"Sarvepalli S, Vadarevu S (2025) Non-antiviral therapies for viral infections: harnessing host mechanisms. Int Immunopharmacol 153:114521","journal-title":"Int Immunopharmacol"},{"key":"2193_CR98","doi-asserted-by":"publisher","first-page":"106101","DOI":"10.1016\/j.antiviral.2025.106101","volume":"235","author":"A Schreiber","year":"2025","unstructured":"Schreiber A, Ludwig S (2025) Host-targeted antivirals against SARS-CoV-2 in clinical development - Prospect or disappointment? Antiviral Res 235:106101","journal-title":"Antiviral Res"},{"key":"2193_CR99","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.drudis.2021.08.002","volume":"27","author":"J Schuler","year":"2022","unstructured":"Schuler J, Falls Z, Mangione W, Hudson ML, Bruggemann L, Samudrala R (2022) Evaluating the performance of drug-repurposing technologies. Drug Discovery Today 27:49\u201364","journal-title":"Drug Discovery Today"},{"key":"2193_CR100","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1080\/17460441.2021.1918098","volume":"16","author":"MSM Serafim","year":"2021","unstructured":"Serafim MSM, Dos Santos J\u00fanior VS, Gertrudes JC, Maltarollo VG, Honorio KM (2021) Machine learning techniques applied to the drug design and discovery of new antivirals: a brief look over the past decade. Expert Opin Drug Discov 16:961\u2013975","journal-title":"Expert Opin Drug Discov"},{"key":"2193_CR101","doi-asserted-by":"publisher","first-page":"e0104521","DOI":"10.1128\/AAC.01045-21","volume":"65","author":"S Shah","year":"2021","unstructured":"Shah S, Ackley TW, Topal JE (2021) Renal and Hepatic Toxicity Analysis of Remdesivir Formulations: Does What Is on the Inside Really Count? Antimicrob Agents Chemother 65:e0104521","journal-title":"Antimicrob Agents Chemother"},{"key":"2193_CR102","first-page":"150","volume":"127","author":"MA Shamim","year":"2023","unstructured":"Shamim MA, Padhi BK, Satapathy P, Veeramachaneni SD, Chatterjee C, Tripathy S, Akhtar N, Pradhan A, Dwivedi P, Mohanty A, Rodriguez-Morales AJ, Sah R, Al-Tammemi AB, Al-Tawfiq JA, Nowrouzi-Kia B, Chattu VK (2023a) The use of antivirals in the treatment of human monkeypox outbreaks: a systematic review. Int J Infect diseases: IJID : official publication Int Soc Infect Dis 127:150\u2013161","journal-title":"Int J Infect diseases: IJID : official publication Int Soc Infect Dis"},{"key":"2193_CR103","doi-asserted-by":"publisher","first-page":"1149909","DOI":"10.3389\/fphar.2023.1149909","volume":"14","author":"MA Shamim","year":"2023","unstructured":"Shamim MA, Satapathy P, Padhi BK, Veeramachaneni SD, Akhtar N, Pradhan A, Agrawal A, Dwivedi P, Mohanty A, Pradhan KB, Kabir R, Rabaan AA, Alotaibi J, Al Ismail ZA, Alsoliabi ZA, Al Fraij A, Sah R, Rodriguez-Morales AJ (2023b) Pharmacological treatment and vaccines in monkeypox virus: a narrative review and bibliometric analysis. Front Pharmacol 14:1149909","journal-title":"Front Pharmacol"},{"key":"2193_CR104","unstructured":"Shawa IT (2019) Hepatitis B and C viruses. IntechOpen"},{"key":"2193_CR105","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/cid\/ciac622","volume":"76","author":"EA Siegrist","year":"2023","unstructured":"Siegrist EA, Sassine J (2023) Antivirals With Activity Against Mpox: A Clinically Oriented Review. Clin Infect diseases: official publication Infect Dis Soc Am 76:155\u2013164","journal-title":"Clin Infect diseases: official publication Infect Dis Soc Am"},{"key":"2193_CR106","doi-asserted-by":"publisher","first-page":"100071","DOI":"10.1016\/j.aichem.2024.100071","volume":"2","author":"A Singh","year":"2024","unstructured":"Singh A (2024) Artificial intelligence for drug repurposing against infectious diseases. Artif Intell Chem 2:100071","journal-title":"Artif Intell Chem"},{"key":"2193_CR107","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s43440-020-00155-6","volume":"72","author":"TU Singh","year":"2020","unstructured":"Singh TU, Parida S, Lingaraju MC, Kesavan M, Kumar D, Singh RK (2020) Drug repurposing approach to fight COVID-19. Pharmacol Rep 72:1479\u20131508","journal-title":"Pharmacol Rep"},{"key":"2193_CR108","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2217\/fvl.13.98","volume":"8","author":"DF Smee","year":"2013","unstructured":"Smee DF, Tarbet EB, Furuta Y, Morrey JD, Barnard DL (2013) Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice. Future Virol 8:1085\u20131094","journal-title":"Future Virol"},{"key":"2193_CR109","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/1756283X13515825","volume":"7","author":"C Stedman","year":"2014","unstructured":"Stedman C (2014) Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. Therapeutic Adv Gastroenterol 7:131\u2013140","journal-title":"Therapeutic Adv Gastroenterol"},{"key":"2193_CR112","doi-asserted-by":"publisher","first-page":"bbab526","DOI":"10.1093\/bib\/bbab526","volume":"23","author":"X Su","year":"2022","unstructured":"Su X, Hu L, You Z, Hu P, Wang L, Zhao B (2022) A deep learning method for repurposing antiviral drugs against new viruses via multi-view nonnegative matrix factorization and its application to SARS-CoV-2. Brief Bioinform 23:bbab526","journal-title":"Brief Bioinform"},{"key":"2193_CR110","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.3390\/molecules28155920","volume":"28","author":"J Su","year":"2023","unstructured":"Su J, Lai J, Li J, Li C, Liu X, Wang C, Zhu B, Li Y (2023a) Selenium nanoparticles control h1n1 virus by inhibiting inflammatory response and cell apoptosis. Molecules 28:5920","journal-title":"Molecules"},{"key":"2193_CR111","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.3390\/v15091858","volume":"15","author":"J Su","year":"2023","unstructured":"Su J, Lai J, Li J, Liu X, Chen H, Li C, Zhu B, Jia X, Li Y (2023b) Carambolaside W inhibited H1N1 influenza virus-induced oxidative stress through STAT-3\/BCL-XL signaling pathway. Viruses 15:1858","journal-title":"Viruses"},{"key":"2193_CR113","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s13059-020-02150-9","volume":"21","author":"B Sui","year":"2020","unstructured":"Sui B, Chen D, Liu W, Wu Q, Tian B, Li Y, Hou J, Liu S, Xie J, Jiang H, Luo Z, Lv L, Huang F, Li R, Zhang C, Tian Y, Cui M, Zhou M, Chen H, Fu ZF, Zhang Y, Zhao L (2020) A novel antiviral lncRNA, EDAL, shields a T309 O-GlcNAcylation site to promote EZH2 lysosomal degradation. Genome Biol 21:228","journal-title":"Genome Biol"},{"key":"2193_CR114","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3390\/metabo15010044","volume":"15","author":"MSI Sumon","year":"2025","unstructured":"Sumon MSI, Hossain MSA, Al-Sulaiti H, Yassine HM, Chowdhury MEH (2025) A Comprehensive machine learning approach for COVID-19 target discovery in the small-molecule metabolome. Metabolites 15:44","journal-title":"Metabolites"},{"key":"2193_CR115","doi-asserted-by":"publisher","first-page":"603615","DOI":"10.3389\/fimmu.2020.603615","volume":"11","author":"X Tang","year":"2020","unstructured":"Tang X, Cai L, Meng Y, Xu J, Lu C, Yang J (2020) Indicator regularized non-negative matrix factorization method-based drug repurposing for COVID-19. Front Immunol 11:603615","journal-title":"Front Immunol"},{"key":"2193_CR116","doi-asserted-by":"crossref","unstructured":"Teleb K, Gasimelseed M, Al-Thani R, Aladawi R, Ibrahim MIM (2026) Artificial intelligence and machine learning in pharmacovigilance. a systematic review of models for drug safety in polypharmacy. PrePrints","DOI":"10.20944\/preprints202602.0477.v1"},{"key":"2193_CR117","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1021\/acsinfecdis.0c00456","volume":"6","author":"AM Tharappel","year":"2020","unstructured":"Tharappel AM, Samrat SK, Li Z, Li H (2020) Targeting crucial host factors of SARS-CoV-2. ACS Infect Dis 6:2844\u20132865","journal-title":"ACS Infect Dis"},{"key":"2193_CR118","doi-asserted-by":"publisher","first-page":"100058","DOI":"10.1016\/j.crphar.2021.100058","volume":"2","author":"D Tripathi","year":"2021","unstructured":"Tripathi D, Sodani M, Gupta PK, Kulkarni S (2021) Host directed therapies: COVID-19 and beyond. Curr Res Pharmacol drug discovery 2:100058","journal-title":"Curr Res Pharmacol drug discovery"},{"key":"2193_CR119","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.3390\/jcm9113777","volume":"9","author":"J Trivedi","year":"2020","unstructured":"Trivedi J, Mohan M, Byrareddy SN (2020) Drug repurposing approaches to combating viral infections. J Clin Med 9:3777","journal-title":"J Clin Med"},{"key":"2193_CR120","doi-asserted-by":"publisher","first-page":"106625","DOI":"10.1016\/j.cct.2021.106625","volume":"112","author":"AM Vanderbeek","year":"2022","unstructured":"Vanderbeek AM, Bliss JM, Yin Z, Yap C (2022) Implementation of platform trials in the COVID-19 pandemic: a rapid review. Contemp Clin Trials 112:106625","journal-title":"Contemp Clin Trials"},{"key":"2193_CR121","doi-asserted-by":"publisher","first-page":"104866","DOI":"10.1016\/j.antiviral.2020.104866","volume":"181","author":"N Venisse","year":"2020","unstructured":"Venisse N, Peytavin G, Bouchet S, Gagnieu MC, Garraffo R, Guilhaumou R, Solas C (2020) Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection. Antiviral Res 181:104866","journal-title":"Antiviral Res"},{"key":"2193_CR122","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-023-00692-8","volume":"22","author":"A von Delft","year":"2023","unstructured":"von Delft A, Hall MD, Kwong AD, Purcell LA, Saikatendu KS, Schmitz U, Tallarico JA, Lee AA (2023) Accelerating antiviral drug discovery: lessons from COVID-19. Nat Rev Drug Discov 22:585\u2013603","journal-title":"Nat Rev Drug Discov"},{"key":"2193_CR123","first-page":"e2411325","volume":"12","author":"Z Wan","year":"2025","unstructured":"Wan Z, Sun X, Li Y, Chu T, Hao X, Cao Y, Zhang P (2025) Applications of artificial intelligence in drug repurposing. Adv Sci (Weinheim Baden-Wurttemberg Germany) 12:e2411325","journal-title":"Adv Sci (Weinheim Baden-Wurttemberg Germany)"},{"key":"2193_CR126","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/med.21728","volume":"41","author":"X Wang","year":"2021","unstructured":"Wang X, Guan Y (2021) COVID-19 drug repurposing: a review of computational screening methods, clinical trials, and protein interaction assays. Med Res Rev 41:5\u201328","journal-title":"Med Res Rev"},{"key":"2193_CR124","doi-asserted-by":"crossref","unstructured":"Wang M, Withers JB, Ricchiuto P, Voitalov I, McAnally M, Sanchez HN, Saleh A, Akmaev VR, Ghiassian SD (2021a) A systems-based method to repurpose marketed therapeutics for antiviral use: a SARS-CoV-2 case study. Life Sci Alliance 4","DOI":"10.26508\/lsa.202000904"},{"key":"2193_CR127","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/eji.202048975","volume":"51","author":"X Wang","year":"2021","unstructured":"Wang X, Xia H, Liu S, Cao L, You F (2021b) Epigenetic regulation in antiviral innate immunity. Eur J Immunol 51:1641\u20131651","journal-title":"Eur J Immunol"},{"key":"2193_CR128","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3390\/vaccines10111816","volume":"10","author":"Y Wang","year":"2022","unstructured":"Wang Y, Ling L, Zhang Z, Marin-Lopez A (2022) Current advances in Zika vaccine development. Vaccines 10:1816","journal-title":"Vaccines"},{"key":"2193_CR125","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13046-025-03358-y","volume":"44","author":"S Wang","year":"2025","unstructured":"Wang S, Kong L, Wang L, Zhuang Y, Guo C, Zhang Y, Cui H, Gu X, Wu J, Jiang C (2025) Viral expression of NE\/PPE enhances anti-colorectal cancer efficacy of oncolytic adenovirus by promoting TAM M1 polarization to reverse insufficient effector memory\/effector CD8(+) T cell infiltration. J experimental Clin cancer research: CR 44:97","journal-title":"J experimental Clin cancer research: CR"},{"key":"2193_CR129","doi-asserted-by":"crossref","unstructured":"Xue Y, Mei H, Chen Y, Griffin JD, Liu Q, Weisberg E, Yang J (2023) Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV-2. MedComm 4: e254","DOI":"10.1002\/mco2.254"},{"key":"2193_CR130","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1038\/s41591-022-01831-1","volume":"28","author":"R Yajima","year":"2022","unstructured":"Yajima R, More AF, Garvan C, Harper C, Grimes KV (2022) A US clinical trial network is needed for the next pandemic. Nat Med 28:1330\u20131331","journal-title":"Nat Med"},{"key":"2193_CR131","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41746-024-01038-3","volume":"7","author":"C Yan","year":"2024","unstructured":"Yan C, Grabowska ME, Dickson AL, Li B, Wen Z, Roden DM, Michael Stein C, Emb\u00ed PJ, Peterson JF, Feng Q, Malin BA, Wei WQ (2024) Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer\u2019s disease with real-world clinical validation. NPJ Digit Med 7:46","journal-title":"NPJ Digit Med"},{"key":"2193_CR132","doi-asserted-by":"publisher","first-page":"2270194","DOI":"10.1080\/21645515.2023.2270194","volume":"19","author":"X Yang","year":"2023","unstructured":"Yang X, Chen M, Cao L, Zhao M (2023) Bibliometric analysis of scientific papers on adverse reactions to COVID-19 vaccines published between 2019 and 2023. Hum vaccines immunotherapeutics 19:2270194","journal-title":"Hum vaccines immunotherapeutics"},{"key":"2193_CR133","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.bbrc.2023.07.018","volume":"675","author":"Y Yao","year":"2023","unstructured":"Yao Y, Zhang Y, Li Z, Chen Z, Wang X, Li Z, Yu L, Cheng X, Li W, Jiang WJ, Wu HJ, Feng Z, Sun J, Fei T (2023) A deep learning-based drug repurposing screening and validation for anti-SARS-CoV-2 compounds by targeting the cell entry mechanism. Biochem Biophys Res Commun 675:113\u2013121","journal-title":"Biochem Biophys Res Commun"},{"key":"2193_CR134","doi-asserted-by":"publisher","first-page":"8006","DOI":"10.3390\/ijms23148006","volume":"23","author":"P Zagaliotis","year":"2022","unstructured":"Zagaliotis P, Petrou A, Mystridis GA, Geronikaki A, Vizirianakis IS, Walsh TJ (2022) Developing new treatments for COVID-19 through dual-action antiviral\/anti-inflammatory small molecules and physiologically based pharmacokinetic modeling. Int J Mol Sci 23:8006","journal-title":"Int J Mol Sci"},{"key":"2193_CR136","doi-asserted-by":"publisher","first-page":"4624","DOI":"10.1021\/acs.jproteome.0c00316","volume":"19","author":"X Zeng","year":"2020","unstructured":"Zeng X, Song X, Ma T, Pan X, Zhou Y, Hou Y, Zhang Z, Li K, Karypis G, Cheng F (2020) Repurpose open data to discover therapeutics for COVID-19 using deep learning. J Proteome Res 19:4624\u20134636","journal-title":"J Proteome Res"},{"key":"2193_CR135","doi-asserted-by":"publisher","first-page":"22968","DOI":"10.1021\/acsnano.5c02492","volume":"19","author":"J Zeng","year":"2025","unstructured":"Zeng J, Zhang Y, Gao Y, Jia M, Guo Y, Li X, Wang Y, Zhao C, Qiu J, McGinty S, Miao W, Wang G, Wang Y (2025) Biomimetic ginsenoside Rb1 and probucol co-assembled nanoparticles for targeted atherosclerosis therapy via inhibition of oxidative stress, inflammation, and lipid deposition. ACS Nano 19:22968\u201322987","journal-title":"ACS Nano"},{"key":"2193_CR138","doi-asserted-by":"publisher","first-page":"739684","DOI":"10.3389\/fmicb.2021.739684","volume":"12","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Ye T, Xi H, Juhas M, Li J (2021) Deep learning driven drug discovery: tackling severe acute respiratory syndrome coronavirus 2. Front Microbiol 12:739684","journal-title":"Front Microbiol"},{"key":"2193_CR137","doi-asserted-by":"publisher","first-page":"2263229","DOI":"10.1080\/21645515.2023.2263229","volume":"19","author":"HQ Zhang","year":"2023","unstructured":"Zhang HQ, Cao BZ, Cao QT, Hun M, Cao L, Zhao MY (2023) An analysis of reported cases of hemophagocytic lymphohistiocytosis (HLH) after COVID-19 vaccination. Hum vaccines immunotherapeutics 19:2263229","journal-title":"Hum vaccines immunotherapeutics"},{"key":"2193_CR139","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/978-1-4939-8955-3_13","volume":"1903","author":"K Zhao","year":"2019","unstructured":"Zhao K, So HC (2019) Using drug expression profiles and machine learning approach for drug repurposing. Methods Mol Biol (Clifton, NJ) 1903:219\u2013237","journal-title":"Methods Mol Biol (Clifton, NJ)"},{"key":"2193_CR140","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/IM9.0000000000000033","volume":"2","author":"X Zheng","year":"2020","unstructured":"Zheng X, Li L (2020) Potential therapeutic options for COVID-19. Infect microbes Dis 2:89\u201395","journal-title":"Infect microbes Dis"},{"key":"2193_CR141","doi-asserted-by":"publisher","first-page":"9537","DOI":"10.1038\/s41467-025-64552-2","volume":"16","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Zhang Y, Xu H, Chen Z, Huang S, Li Y, Fu J, Zhang H, Zhao D, Lian X, Zhou Y, Shen X, Liu K, Qiu Y, Wang Y, Xie W, Han L, Dai H, Zhu F (2025) Dynamic clinical trial success rates for drugs in the 21st century. Nat Commun 16:9537","journal-title":"Nat Commun"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02193-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-026-02193-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-026-02193-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:08:16Z","timestamp":1776316096000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-026-02193-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":141,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2193"],"URL":"https:\/\/doi.org\/10.1007\/s10787-026-02193-7","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"1 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}